CSIMarket Company Name, Ticker, Competitors, else..
 
Stereotaxis Inc   (NYSEAMER: STXS)
 
Price: $1.2850 $-0.01 -1.154%
Day's High: $1.309999942779541 Week Perf: -6.88 %
Day's Low: $ 1.28 30 Day Perf: -10.76 %
Volume (M): 161,588 52 Wk High: $ 3.59
Volume (M$): $ 0 52 Wk Avg: $2.13
Open: $1.29 52 Wk Low: $1.24



 Market Capitalization (Millions $) 129
 Shares Outstanding (Millions) 100
 Employees 131
 Revenues (TTM) (Millions $) 30
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Stereotaxis Inc. is a medical technology company that specializes in the field of robotic cardiac ablation. The company designs and manufactures systems that use robotic control and navigation technologies for the treatment of cardiac arrhythmias. The Stereotaxis Robotic Magnetic Navigation System allows physicians to remotely navigate and position catheters within the heart using powerful magnets and precise robotic control, providing greater precision and safety during procedures. Stereotaxis Inc. aims to improve patient outcomes and enhance the efficiency of cardiac procedures through their innovative technologies.


   Company Address: 710 North Tucker Boulevard St. Louis 63101 MO
   Company Phone Number: 678-6100   Stock Exchange / Ticker: NYSEAMER STXS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRC        8.36% 
ELMD        0.96% 
INGN   -1.5%    
MDT        1.1% 
RMD   -4.69%    
RVP   -2.76%    
• View Complete Report
   



Product Service News

Navigating Innovation Stereotaxis and CardioFocus Forge Partnership to Revolutionise Robotic Pulsed Field Ablation fo...

Published Tue, Oct 14 2025 8:57 AM UTC

In a strategic alignment borne of necessity and innovation, Stereotaxis (NYSE: STXS), a trailblazer in surgical robotics dedicated to minimally invasive endovascular interventions, announced its collaboration with CardioFocus, Inc., a vanguard in the realm of ablation treatment for cardiac arrhythmias. The Collaboration Agreement, disclosed on October 13, 2025, marks a signi...
Product Service News

Hospital da Luz Pioneers Robotic Surgery in Portugal with Genesis Robotic System

Published Wed, Nov 20 2024 1:18 PM UTC

In a groundbreaking advancement for the field of surgical robotics in Portugal, Hospital da Luz in Lisbon has successfully adopted the Genesis Robotic Magnetic Navigation (RMN) System developed by Stereotaxis, a renowned leader in the realm of minimally invasive endovascular interventions. This landmark achievement marks a significant milestone for both the hospital and the ...
Product Service News

University of Kansas Medical Center Bolsters Heart Care with Advanced Robotic Technology

Published Wed, Nov 6 2024 1:25 PM UTC

In a groundbreaking advancement for cardiac medicine, the University of Kansas Medical Center has successfully integrated the cutting-edge Genesis Robotic Magnetic Navigation (RMN) System, a pioneering technology from Stereotaxis, into its heart care program. This monumental step was marked by the successful treatment of its first patients using this state-of-the-art robotic...
Product Service News

Stereotaxis Advances Cardiac Technology with Regulatory Submissions and Hospital Adoption

Published Mon, Aug 12 2024 8:03 PM UTC

Stereotaxis Inc., a leading player in the field of surgical robotics, has recently made significant strides in advancing its cardiac care technology. The company announced the achievement of a CE mark in Europe and the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its innovative semi-mobile robotic system, GenesisX. This regulatory pro...
Product Service News

Revamping Cardiac Care: Southern Italy's Santa Maria della Pietà Introduces Pioneering Robotic Technology for Heart Rhythm Treatment

Published Wed, May 22 2024 12:42 PM UTC

In a groundbreaking development, the Hospital Santa Maria della Pietà, located in Nola in the Metropolitan City of Naples, has launched Southern Italy s first-ever robotic cardiac heart program. This state-of-the-art technology marks a significant milestone in the region s medical history, promising advanced and precise treatment options for heart rhythm patients.Robotic Ca...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.30
Price to Sales (Expected) -
Price to Book 10.5
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.42
Working Capital Ratio 1.41
Leverage Ratio (MRQ) 3.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.24 $
Revenues (TTM) 0.3 $
Cash Flow (TTM) 0.08 $
Cash 0.11 $
Book Value 0.12 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 228,183
Net Income per Employee (TTM) -170,405
Receivable Turnover Ratio (TTM) 4.98
Inventory Turnover Ratio (TTM) 1.23
Asset Turnover Ratio (TTM) 0.57

Profitability Ratios Current
Gross Margin (MRQ) 58.49 %
Operating Margin (MRQ) -59.56 %
Net Margin (MRQ) -58.25 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Stereotaxis Inc's Segments
Systems    36.48 % of total Revenue
Disposables Service and Accessories    145.54 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.